Drug Profile
Anti-HSV monoclonal antibody - Development Center for Biotechnology/Unknown
Alternative Names: HSV mAb - Development Center for BiotechnologyLatest Information Update: 18 Jan 2024
Price :
$50
*
At a glance
- Originator Development Center for Biotechnology
- Developer Development Center for Biotechnology; Unknown
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Herpes simplex virus infections
Most Recent Events
- 18 Jan 2024 Anti-HSV monoclonal antibody is in phase-I development in Herpes-simplex-virus-infections in USA (Parenteral) (Development Center for Biotechnology pipeline, January 2024)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections in USA (Parenteral)
- 30 Nov 2020 The anti-HSV monoclonal antibody is still in phase I development in USA (Development Center for Biotechnology pipeline, November 2020)